Start-up - Innovation Managament and Business Development

MIV Therapeutics Inc. anti-restenosis coronary stent

Because of the need for a better manufacturing process and stent design, an anti-restenosis stent can dramatically reduce post implant complications and enhance the life of people with coronary disease.

MIV Therapeutics saw great potential for a more affordable and efficacious coronary stent that improves the prevention of restenosis.

Cria's consulting team improved many aspects of earlier business strategies and product development plans. A stent was created with pockets to store special restenosis-preventing medications and a manufacturing process based on cutting edge laser technology allowed efficient and low cost production for this high performance device.

The impact of this radical change in early plans created a robust fundraising initiative, brought the product to a successful pre-clinical stage at the Mayo Clinic, and allowed the executive team to list MIV Therapeutics on the American stock exchange, NASDAQ.